# BPC-157 + TB-500

> The two most-studied repair peptides pre-mixed — BPC-157 for angiogenesis and tendon/gut healing, TB-500 for actin-driven cell migration.

- Also known as: BPC-157/TB-500, BPC157 TB500, BPC-157 TB-500 blend
- Class: Healing & Repair
- FDA approved: No
- Canonical page: https://americanpeptide.com/catalog/bpc-157-tb-500

## Overview

A combination of the gastric pentadecapeptide BPC-157 and TB-500 (the synthetic fragment of Thymosin β4). The two are paired on the rationale that they act on different limbs of tissue repair — BPC-157 on angiogenesis, growth-factor expression, and the nitric-oxide system; TB-500 on actin regulation and cell migration — so a blend is proposed to cover more of the healing cascade than either alone. It is a research combination: the peptides are studied individually in preclinical work, and no controlled study has tested the mixture or any fixed ratio in humans.

BPC-157 and TB-500 are the two peptides most often combined in the recovery literature because their proposed mechanisms sit at different points of the repair cascade. BPC-157 is studied for angiogenesis, tendon-to-bone healing, and gut-lining protection; TB-500 for the actin dynamics that drive cell migration into a wound. The pairing is a hypothesis that covering both ends of the process does more than either peptide alone.

That hypothesis has not been tested as a blend. The human evidence for each component is itself limited and largely preclinical, and combining two research peptides does not combine their evidence — it compounds the unknowns around purity, stability in a shared vial, and interaction. This is a research reference, not a protocol; neither component is FDA-approved.

## Mechanism

BPC-157: angiogenesis, VEGFR2/eNOS signaling, growth-factor upregulation. TB-500: G-actin sequestration promoting cell migration and wound closure. Mechanisms are complementary, not additive by any measured synergy.

## Research areas

Studied in: Tendon and ligament repair (preclinical), Soft-tissue healing, Angiogenesis.

## Key research

- Complementary targets — BPC-157 (angiogenesis) and TB-500 (cell migration) act on different steps of repair, the basis for pairing them.
- No combined trial — the blend itself has not been studied in controlled human research; evidence is per-component and preclinical.
- Co-formulation unknowns — two peptides sharing one solution raise stability and compatibility questions a single-peptide vial does not.
- Not FDA-approved — neither component is an approved therapeutic.

## Storage, handling & synthesis

**Storage.** Store lyophilized, frozen, and protected from light; once reconstituted, keep refrigerated and use within a short window. A blend is only as stable as its least stable component.

**Handling.** Handle as two peptides in one vial: reconstitute gently without vortexing, and read any certificate as needing per-component identity and purity data rather than a single blended figure.

**Synthesis.** This is a physical mixture, not a single molecule. BPC-157 and TB-500 are each synthesized and purified separately, so there is no combined synthesis and no single purity number — a meaningful certificate shows a separate identity and purity assay for each peptide plus the amount of each in the vial. Two peptides sharing one lyophilized cake and one solution also raise stability and compatibility questions a single-peptide product does not.

## FAQs

### What is the BPC-157 + TB-500 blend?

A pre-mixed combination of two repair peptides — BPC-157 and TB-500 — paired for their complementary roles in angiogenesis and cell migration. It is a research combination, not an approved therapy.

### Is the blend studied as a combination?

No. Each peptide is studied separately, mostly in preclinical models. No controlled study has tested the mixture or a fixed ratio, so combined effects are unestablished.

### Why are these two paired?

Their proposed mechanisms sit at different points of the healing cascade — BPC-157 on angiogenesis and growth factors, TB-500 on actin-driven cell migration — so the pairing aims to cover more of the process.

### Is it approved?

No — neither component is FDA-approved. This page is a research and educational reference, not medical advice.

---

Source: AmericanPeptide.com — https://americanpeptide.com/catalog/bpc-157-tb-500
Data license: CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). Attribution: AmericanPeptide.com.
Research reference only — computational and educational content, not medical advice.